Weekly paclitaxel (wP) as single agent or in combination with weekly topotecan (wT) or carboplatin (C) in patients with resistant ovarian cancer (ROC): The phase II CARTAXHY randomized trial from GINECO

Laurence Gladieff,Alain Lortholary,R. Largillier,B. Weber,J. Alexandre,X. Durando,B Slama,Jérôme Dauba,D. Paraiso,Eric Pujade Lauraine

Weekly paclitaxel (wP) as single agent or in combination with weekly topotecan (wT) or carboplatin (C) in patients with resistant ovarian cancer (ROC): The phase II CARTAXHY randomized trial from GINECO

2009

Laurence Gladieff
Alain Lortholary
R. Largillier
B. Weber
J. Alexandre
X. Durando
B Slama
Jérôme Dauba
D. Paraiso
Eric Pujade Lauraine

5557 Background: For ROC patients (pts) with early progression during or after (< 6 months) platinum and 3 weekly P, use of single non-platinum agent including wP is standard (Kristensen G, et al. ...

Keywords:

Ovarian cancer
Carboplatin
Randomized controlled trial
Paclitaxel
Topotecan
Cancer research
Medicine
Oncology
Internal medicine
Pathology
in patient
weekly paclitaxel
single agent

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations